Acute Lymphoblastic Leukemia

Previously Untreated

Age 18-39

SWOGA041501
Phase III inotuzumab Ozogamicin (Anti-CD22 Mab) vs Frontline Tx in Newly Diagnosed Precursor B-Cell ALL

PI: Liedtke
SWOG

Age 30-70

SWOG E1910
Phase III Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage ALL

PI: Liedtke
SWOG

Relapsed/Refractory

SWOGS1312
Phase I Inotuzumab Ozogamicin with CVP in Relapsed/Refractory CD22 + Acute Leukemia

PI: Liedtke
SWOG

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold